CY1107704T1 - Συνθεσεις υδροπηκτης για την ελεγχομενης αποδεσμευσης χορηγηση αυξητικων παραγοντων - Google Patents

Συνθεσεις υδροπηκτης για την ελεγχομενης αποδεσμευσης χορηγηση αυξητικων παραγοντων

Info

Publication number
CY1107704T1
CY1107704T1 CY20071101034T CY071101034T CY1107704T1 CY 1107704 T1 CY1107704 T1 CY 1107704T1 CY 20071101034 T CY20071101034 T CY 20071101034T CY 071101034 T CY071101034 T CY 071101034T CY 1107704 T1 CY1107704 T1 CY 1107704T1
Authority
CY
Cyprus
Prior art keywords
controlled release
growth factors
compositions
release adjustment
aquaculture
Prior art date
Application number
CY20071101034T
Other languages
English (en)
Inventor
Robert N Jennings Jr
Bing Yang
Andrew A Protter
Yu-Chang John Wang
Original Assignee
Scios Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scios Inc. filed Critical Scios Inc.
Publication of CY1107704T1 publication Critical patent/CY1107704T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A61K38/1866—Vascular endothelial growth factor [VEGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Συνθέσεις και μέθοδοι γνωστοποιούνται για την ελεγχόμενης αποδέσμευσης παροχή πολυπεπτιδικών αυξητικών παραγόντων. Οι συνθέσεις της εφεύρεσης είναι υδροπηκτές οι οποίες περιλαμβάνουν: έναν πολυπεπτιδικό αυξητικό παράγοντα ο οποίος έχει τουλάχιστον μία περιοχή θετικού φορτίου· ένα φυσιολογικώς αποδεκτό αναμείξιμο με το νερό ανιοντικό πολυμερές· έναν φυσιολογικώς αποδεκτό μη-ιοντικό πολυμερικό παράγοντα ελέγχου του ιξώδους· και νερό.
CY20071101034T 1998-09-04 2007-08-02 Συνθεσεις υδροπηκτης για την ελεγχομενης αποδεσμευσης χορηγηση αυξητικων παραγοντων CY1107704T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9916898P 1998-09-04 1998-09-04
EP99946759A EP1107791B8 (en) 1998-09-04 1999-09-03 Hydrogel compositions for the controlled release administration of growth factors

Publications (1)

Publication Number Publication Date
CY1107704T1 true CY1107704T1 (el) 2013-04-18

Family

ID=22273280

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20071101034T CY1107704T1 (el) 1998-09-04 2007-08-02 Συνθεσεις υδροπηκτης για την ελεγχομενης αποδεσμευσης χορηγηση αυξητικων παραγοντων

Country Status (13)

Country Link
US (1) US6331309B1 (el)
EP (1) EP1107791B8 (el)
JP (2) JP2002524425A (el)
AT (1) ATE363292T1 (el)
AU (1) AU758178B2 (el)
CA (1) CA2341410C (el)
CY (1) CY1107704T1 (el)
DE (1) DE69936212T2 (el)
DK (1) DK1107791T3 (el)
ES (1) ES2288024T3 (el)
IL (2) IL141688A0 (el)
PT (1) PT1107791E (el)
WO (1) WO2000013710A2 (el)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1178834B1 (en) * 1999-04-22 2006-01-04 Eidgenössische Technische Hochschule (ETH) Controlled release of growth factors from heparin containing matrices
AU2001263281A1 (en) * 2000-05-18 2001-11-26 Genetix Pharmaceuticals, Inc. Polyethylene glycol (peg) polymers for the promotion of angiogenesis
AR034517A1 (es) * 2001-06-21 2004-02-25 Astrazeneca Ab Formulacion farmaceutica
US6818613B2 (en) * 2001-11-07 2004-11-16 Ortho-Mcneil Pharmaceutical, Inc. Aqueous sustained-release formulations of proteins
AU2002365162A1 (en) 2001-11-14 2003-07-09 Northwestern University Self-assembly and mineralization of peptide-amphiphile nanofibers
US8608661B1 (en) 2001-11-30 2013-12-17 Advanced Cardiovascular Systems, Inc. Method for intravascular delivery of a treatment agent beyond a blood vessel wall
JP2003238439A (ja) * 2002-02-13 2003-08-27 Yasuhiko Tabata 虚血治療剤
US7371719B2 (en) 2002-02-15 2008-05-13 Northwestern University Self-assembly of peptide-amphiphile nanofibers under physiological conditions
CA2483265A1 (en) * 2002-04-25 2003-11-06 Clyde L. Schultz Growth factor delivery system for the healing of wounds and the prevention of inflammation and disease
US20030203032A1 (en) * 2002-04-25 2003-10-30 Schultz Clyde L. Growth factor delivery system for the healing of wounds and the prevention of inflammation and disease
SE0201659D0 (sv) 2002-05-31 2002-05-31 Astrazeneca Ab Modified release pharmaceutical formulation
SE0201661D0 (sv) 2002-05-31 2002-05-31 Astrazeneca Ab New salts
US7361368B2 (en) 2002-06-28 2008-04-22 Advanced Cardiovascular Systems, Inc. Device and method for combining a treatment agent and a gel
WO2004018628A2 (en) 2002-08-21 2004-03-04 Northwestern University Charged peptide-amphiphile solutions & self-assembled peptide nanofiber networks formed therefrom
JP2004115413A (ja) * 2002-09-25 2004-04-15 Yasuhiko Tabata 冠状動脈狭窄または閉塞治療用徐放性製剤
US7554021B2 (en) 2002-11-12 2009-06-30 Northwestern University Composition and method for self-assembly and mineralization of peptide amphiphiles
WO2004046167A2 (en) 2002-11-14 2004-06-03 Northwestern University Synthesis and self-assembly of abc triblock bola peptide
MXPA05008483A (es) 2003-02-11 2006-03-10 Univ Northwestern Metodos y materiales para revestimientos de superficie nanocristalinos y union de nanofibras de anfililos peptidicos sobre las mismas.
US9216106B2 (en) 2003-04-09 2015-12-22 Directcontact Llc Device and method for the delivery of drugs for the treatment of posterior segment disease
US20050074497A1 (en) * 2003-04-09 2005-04-07 Schultz Clyde L. Hydrogels used to deliver medicaments to the eye for the treatment of posterior segment diseases
US20050255144A1 (en) * 2003-04-09 2005-11-17 Directcontact Llc Methods and articles for the delivery of medicaments to the eye for the treatment of posterior segment diseases
US8821473B2 (en) 2003-04-15 2014-09-02 Abbott Cardiovascular Systems Inc. Methods and compositions to treat myocardial conditions
US8038991B1 (en) 2003-04-15 2011-10-18 Abbott Cardiovascular Systems Inc. High-viscosity hyaluronic acid compositions to treat myocardial conditions
US7641643B2 (en) 2003-04-15 2010-01-05 Abbott Cardiovascular Systems Inc. Methods and compositions to treat myocardial conditions
ES2380340T3 (es) 2003-12-05 2012-05-10 Northwestern University Anfífilos peptídicos auto-ensamblantes y métodos relacionados para la administración de factores de crecimiento
CN1905893A (zh) 2003-12-05 2007-01-31 西北大学 分支的肽两亲物、相关的表位组合物和其自组装的结构
AU2005309854A1 (en) * 2004-11-24 2006-06-01 Therakine Ltd. An implant for intraocular drug delivery
NZ560649A (en) 2005-03-04 2011-03-31 Univ Northwestern Angiogenic heparin binding peptide amphiphiles, peptide amphiphiles, self-assembled composition and related methods of use
US20080125745A1 (en) 2005-04-19 2008-05-29 Shubhayu Basu Methods and compositions for treating post-cardial infarction damage
US9539410B2 (en) 2005-04-19 2017-01-10 Abbott Cardiovascular Systems Inc. Methods and compositions for treating post-cardial infarction damage
US8828433B2 (en) 2005-04-19 2014-09-09 Advanced Cardiovascular Systems, Inc. Hydrogel bioscaffoldings and biomedical device coatings
US7732190B2 (en) 2006-07-31 2010-06-08 Advanced Cardiovascular Systems, Inc. Modified two-component gelation systems, methods of use and methods of manufacture
US9242005B1 (en) 2006-08-21 2016-01-26 Abbott Cardiovascular Systems Inc. Pro-healing agent formulation compositions, methods and treatments
US9005672B2 (en) 2006-11-17 2015-04-14 Abbott Cardiovascular Systems Inc. Methods of modifying myocardial infarction expansion
US8741326B2 (en) 2006-11-17 2014-06-03 Abbott Cardiovascular Systems Inc. Modified two-component gelation systems, methods of use and methods of manufacture
US8192760B2 (en) 2006-12-04 2012-06-05 Abbott Cardiovascular Systems Inc. Methods and compositions for treating tissue using silk proteins
US8076295B2 (en) 2007-04-17 2011-12-13 Nanotope, Inc. Peptide amphiphiles having improved solubility and methods of using same
KR20190026056A (ko) 2008-04-21 2019-03-12 오토노미, 인코포레이티드 귀 질환 및 병태를 치료하기 위한 귀 조제물
US11969501B2 (en) 2008-04-21 2024-04-30 Dompé Farmaceutici S.P.A. Auris formulations for treating otic diseases and conditions
US8496957B2 (en) 2008-07-21 2013-07-30 Otonomy, Inc Controlled release auris sensory cell modulator compositions and methods for the treatment of otic disorders
US9248159B2 (en) 2008-10-14 2016-02-02 Robert Stanley Berman MRSA bactericidal topical gel
KR101101321B1 (ko) * 2008-11-03 2012-01-02 주식회사 엠씨티티 상처 치유를 위한 하이드로 겔 형태의 세포전달용 비히클 및 그 제조방법
KR101163171B1 (ko) * 2009-01-20 2012-07-19 (주)케어젠 노긴?유래 펩타이드 및 그의 용도
US8450271B2 (en) 2009-04-13 2013-05-28 Northwestern University Peptide-based scaffolds for cartilage regeneration and methods for their use
SG11201507429TA (en) 2013-03-15 2015-10-29 Genentech Inc Il-22 polypeptides and il-22 fc fusion proteins and methods of use
WO2015088990A1 (en) 2013-12-09 2015-06-18 Durect Corporation Pharmaceutically active agent complexes, polymer complexes, and compositions and methods involving the same
AU2016382614A1 (en) * 2015-12-04 2018-07-19 President And Fellows Of Harvard College Devices, methods, and compositions for restricting cell position and stabilizing cells in culture systems
AU2019212703A1 (en) 2018-01-26 2020-08-13 Genentech, Inc. Compositions and methods of use
AR114565A1 (es) 2018-01-26 2020-09-23 Genentech Inc Proteínas de fusión fc il-22 y métodos de uso
EP3755364A1 (en) 2018-02-21 2020-12-30 F. Hoffmann-La Roche AG Dosing for treatment with il-22 fc fusion proteins

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4100271A (en) 1976-02-26 1978-07-11 Cooper Laboratories, Inc. Clear, water-miscible, liquid pharmaceutical vehicles and compositions which gel at body temperature for drug delivery to mucous membranes
US5705485A (en) 1987-09-18 1998-01-06 Ethicon, Inc. Gel formulations containing growth factors
NZ226171A (en) * 1987-09-18 1990-06-26 Ethicon Inc Gel formulation containing polypeptide growth factor
US5457093A (en) 1987-09-18 1995-10-10 Ethicon, Inc. Gel formulations containing growth factors
US5100668A (en) * 1988-06-14 1992-03-31 Massachusetts Institute Of Technology Controlled release systems containing heparin and growth factors
US5013769A (en) * 1988-08-22 1991-05-07 Medipro Sciences Limited Method of making a hydrogel-forming wound dressing or skin coating material
US5470829A (en) 1988-11-17 1995-11-28 Prisell; Per Pharmaceutical preparation
FR2644066B1 (fr) 1989-03-09 1994-05-13 Therapeutiques Substitutives Compositions stabilisees comprenant des fgfs, leur procede d'obtention et leurs applications therapeutiques, chirurgicales et cosmetologiques
US5271943A (en) * 1989-10-27 1993-12-21 Scott Health Care Wound gel compositions containing sodium chloride and method of using them
US5591709A (en) * 1991-08-30 1997-01-07 Life Medical Sciences, Inc. Compositions and methods for treating wounds
EP0551626A1 (en) * 1991-12-19 1993-07-21 LEK, tovarna farmacevtskih in kemicnih izdelkov, d.d. Thermoreversible gel as a liquid pharmaceutical carrier for a galenic formulation
US5952006A (en) * 1995-09-29 1999-09-14 L.A.M. Pharmaceuticals, Llc Drug preparations for treating impotency
FR2740678B1 (fr) * 1995-11-06 1999-05-14 Oreal Utilisation en cosmetique d'une composition solide ayant une matrice gelifiee et compositions cosmetiques ou dermatologiques mises en oeuvre
ATE322282T1 (de) * 1996-08-16 2006-04-15 Mcw Res Found Inc Knochen morphogenetisches protein und fibroblasten wachstumsfaktor enthaltende zusammensetzungen und methoden zur induzierung der kardiogenese
US6103266A (en) * 1998-04-22 2000-08-15 Tapolsky; Gilles H. Pharmaceutical gel preparation applicable to mucosal surfaces and body tissues

Also Published As

Publication number Publication date
JP2002524425A (ja) 2002-08-06
DE69936212T2 (de) 2008-01-24
WO2000013710A3 (en) 2000-06-02
AU758178B2 (en) 2003-03-20
CA2341410A1 (en) 2000-03-16
US6331309B1 (en) 2001-12-18
IL141688A (en) 2006-07-05
PT1107791E (pt) 2007-07-06
AU5909599A (en) 2000-03-27
WO2000013710A2 (en) 2000-03-16
EP1107791B8 (en) 2007-11-07
DK1107791T3 (da) 2007-09-03
IL141688A0 (en) 2002-03-10
CA2341410C (en) 2007-11-20
JP2011021045A (ja) 2011-02-03
EP1107791A2 (en) 2001-06-20
DE69936212D1 (de) 2007-07-12
EP1107791B1 (en) 2007-05-30
ATE363292T1 (de) 2007-06-15
JP5576772B2 (ja) 2014-08-20
ES2288024T3 (es) 2007-12-16

Similar Documents

Publication Publication Date Title
CY1107704T1 (el) Συνθεσεις υδροπηκτης για την ελεγχομενης αποδεσμευσης χορηγηση αυξητικων παραγοντων
CA2317441A1 (en) Intraocular lens coating compositions
DE69930763D1 (en) Tgf-g beta inhibitor-peptide
TW386983B (en) Air controlling polymeric superplasticizers, cement compositions comprising the same and method for making an air controlling hydraulic cement composition
WO1993022987A3 (en) Gel composition for implant and method
BR0013626A (pt) Escova oral, corpo de escova oral, e, processos para produzir um corpo de escova oral, e para produzir uma escova oral
AU2002251725A1 (en) Compositions and methods for biomedical applications
AU2001251287A1 (en) Ophthalmic lenses and compositions, and methods for producing same
BR0012908A (pt) Método para preparar uma composição oral estável antibacteriana contendo uma lupulona hidrogenada, e, composição oral estável antibacteriana
AP1414A (en) Controlled release galantamine composition.
AU2001290837A1 (en) Use of a polypeptide comprising the extracellular domains of il-20rb for the treatment of inflammation
EP2278022A3 (en) Expression vectors, transfection systems, and method of use thereof
WO2000037056A3 (en) Composition and method for treating glaucoma
AU3771597A (en) Novel benzamidines
ZA979961B (en) 5-HT1F agonists
AU2002352832A1 (en) 3-alkylated-5,5',6,6',7,7',8,8'-octahydro-2,2'-binaphthols and 3,3'-dialkylated-5,5',6,6',7,7',8,8'-octahydro-2,2'-binaphthols and processes for making them
AU2001292881A1 (en) Use of recombinant gene delivery vectors for treating or preventing diseases of the eye
PT920483E (pt) Composicoes estaveis a base de poliorgano-siloxanos com grupos funcionais reticulaveis e a sua utilizacao para a producao de revestimentos anti-aderentes
AU697005B2 (en) Implantable molded articles for the administration of active substances to plants
AU6047700A (en) Block copolymers prepared by controlled radical polymerization and their use as flow modifiers
AU3037697A (en) Use of alpha-alkylglucosides and alpha-alkylglucoside esters as anti-microbial emulsifying agents
ZA200003768B (en) Methods and compositions for treating diseases and conditions of the eye.
AU1869601A (en) Pharmaceutical compositions comprising trimegestone
CA2262769A1 (en) Low viscosity, high solids content slurry
AU1230800A (en) Controlled delivery of antidepressants